Home > BNSSG ICB > Development Area >

Vaccinations (DRAFT)

Checked: not set yet by Jenny Henry Next Review: not set yet

Overview

Selective Immunisation Programmes
Target group	Age and schedule	Disease	Vaccines required
Babies born to hepatitis B infected mothers	At birth, 4 weeks and 12 months old	Hepatitis B	Hepatitis B (Engerix B/HBvaxPRO)
Infants in areas of the country with tuberculosis (TB) incidence >= 40/100,000	Around 28 days old	Tuberculosis	BCG
Infants with a parent or grandparent born in a high incidence country	Around 28 days old	Tuberculosis	BCG
Children in a clinical risk group	From 6 months to 17 years of age	Influenza	LAIV or inactivated flu vaccine if contraindicated to LAIV or under 2 years of age
Pregnant women	At any stage of pregnancy during flu season	Influenza	Inactivated flu vaccine
	From 16 weeks gestation	Pertussis	Tdap (ADACEL)
	From 28 weeks gestation	RSV	RSV vaccine (Abrysvo)

Routine Immunisation Schedule

When	Diseases protected against	Vaccine given
8 weeks old	Diphtheria, tetanus, pertussis (whooping cough), polio, Haemophilus influenzae type b (Hib) and hepatitis B	DTaP/IPV/Hib/HepB
	Meningococcal group B (MenB)	MenB
	Rotavirus gastroenteritis	Rotavirus
12 weeks old	Diphtheria, tetanus, pertussis, polio, Hib and hepatitis B	DTaP/IPV/Hib/HepB
	Pneumococcal (13 serotypes)	Pneumococcal conjugate vaccine (PCV)
	Rotavirus	Rotavirus
16 weeks old	Diphtheria, tetanus, pertussis, polio, Hib and hepatitis B	DTaP/IPV/Hib/HepB
	MenB	MenB
One year old (on or after the child’s first birthday)	Hib and Meningococcal group C (MenC)	Hib/MenC
	Pneumococcal	PCV booster
	Measles, mumps and rubella (German measles)	MMR
	MenB	MenB booster
Eligible paediatric age group	Influenza (each year from September)	Live attenuated influenza vaccine LAIV
3 years 4 months old or soon after	Diphtheria, tetanus, pertussis and polio	dTaP/IPV
	Measles, mumps and rubella	MMR (check first dose given)
Boys and girls aged 12 to 13 years	Cancers and genital warts caused by specific human papillomavirus (HPV) types	HPV
14 years old (school Year 9)	Tetanus, diphtheria and polio	Td/IPV (check MMR status)
	Meningococcal groups A, C, W and Y	MenACWY
65 years old	Pneumococcal (23 serotypes)	Pneumococcal polysaccharide vaccine (PPV23)
65 years of age and older	Influenza (each year from September)	Inactivated influenza vaccine
65 from September 2023	Shingles	Shingles vaccine
70 to 79 years of age (plus eligible age groups and severely immunosuppressed)	Shingles	Shingles vaccine
75 years old	Respiratory syncytial virus (RSV)	RSV vaccine

Selective Immunisation Programmes

Selective Immunisation Programmes
Target group	Age and schedule	Disease	Vaccines required
Babies born to hepatitis B infected mothers	At birth, 4 weeks and 12 months old	Hepatitis B	Hepatitis B (Engerix B/HBvaxPRO)
Infants in areas of the country with tuberculosis (TB) incidence >= 40/100,000	Around 28 days old	Tuberculosis	BCG
Infants with a parent or grandparent born in a high incidence country	Around 28 days old	Tuberculosis	BCG
Children in a clinical risk group	From 6 months to 17 years of age	Influenza	LAIV or inactivated flu vaccine if contraindicated to LAIV or under 2 years of age
Pregnant women	At any stage of pregnancy during flu season	Influenza	Inactivated flu vaccine
	From 16 weeks gestation	Pertussis	Tdap (ADACEL)
	From 28 weeks gestation	RSV	RSV vaccine (Abrysvo)

Additional vaccines for individuals with underlying medical conditions

Additional vaccines for individuals with underlying medical conditions
Medical condition	Diseases protected against	Vaccines required
Asplenia or splenic dysfunction (including due to sickle cell and coeliac disease)	Meningococcal groups A, B, C, W and Y	MenACWY
	Meningococcal groups A, B, C, W and Y	MenB
	Pneumococcal	PCV13 (up to 10 years of age)
	Pneumococcal	PPV23 (from 2 years of age)
	Influenza	Annual flu vaccine
Cochlear implants	Pneumococcal	PCV13 (up to 10 years of age)
Cochlear implants	Pneumococcal	PPV23 (from 2 years of age)
Chronic respiratory and heart conditions (such as severe asthma, chronic pulmonary disease, and heart failure)	Pneumococcal	PCV13 (up to 10 years of age)
	Pneumococcal	PPV23 (from 2 years of age)
	Influenza	Annual flu vaccine
Chronic neurological conditions (such as Parkinson’s or motor neurone disease, or learning disability)	Pneumococcal (only if the individual is also at increased risk of aspiration)	PCV13 (up to 10 years of age)
		PPV23 (from 2 years of age)
	Influenza	Annual flu vaccine
Diabetes	Pneumococcal	PCV13 (up to 10 years of age)
	Pneumococcal	PPV23 (from 2 years of age)
	Influenza	Annual flu vaccine
Chronic kidney disease (CKD) (including haemodialysis)	Pneumococcal (stage 4 and 5 CKD)	PCV13 (up to 10 years of age)
	Pneumococcal (stage 4 and 5 CKD)	PPV23 (from 2 years of age)
	Influenza (stage 3, 4 and 5 CKD)	Annual flu vaccine
	Hepatitis B (stage 4 and 5 CKD)	Hepatitis B
Chronic liver conditions	Pneumococcal	PCV13 (up to 10 years of age)
	Pneumococcal	PPV23 (from 2 years of age)
	Influenza	Annual flu vaccine
	Hepatitis A	Hepatitis A
	Hepatitis B	Hepatitis B
Haemophilia	Hepatitis A	Hepatitis A
Haemophilia	Hepatitis B	Hepatitis B
Immunosuppression due to disease or treatment [footnote 15]	Pneumococcal	PCV13 (up to 10 years of age)
	Pneumococcal	PPV23 (from 2 years of age)
	Shingles vaccine	Shingrix – over 50 years of age
	Influenza	Annual flu vaccine
Complement disorders (including those receiving complement inhibitor therapy)	Meningococcal groups A, B, C, W and Y	MenACWY
	Meningococcal groups A, B, C, W and Y	MenB
	Pneumococcal	PCV13 (up to 10 years of age)
	Pneumococcal	PPV23 (from 2 years of age)
	Influenza	Annual flu vaccine

Resources

with a note.

Resources

Immunisation against infectious disease - GOV.UK (The Green Book)

Efforts are made to ensure the accuracy and agreement of these guidelines, including any content uploaded, referred to or linked to from the system. However, BNSSG ICB cannot guarantee this. This guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, in accordance with the mental capacity act, and informed by the summary of product characteristics of any drugs they are considering. Practitioners are required to perform their duties in accordance with the law and their regulators and nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

Information provided through Remedy is continually updated so please be aware any printed copies may quickly become out of date.